Tag Archives: hiv

Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

by Fred C. Semitala, Jillian L. Kadota, Allan Musinguzi, Fred Welishe, Anne Nakitende, Lydia Akello, Lynn Kunihira Tinka, Jane Nakimuli, Joan Ritar Kasidi, Opira Bishop, Suzan Nakasendwa, Yeonsoo Baik, Devika Patel, Amanda Sammann, Payam Nahid, Robert Belknap, Moses R. Kamya, … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , , , , | Comments Off on Comparison of 3 optimized delivery strategies for completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV in Uganda: A single-center randomized trial

Estimating the impact of alternative programmatic cotrimoxazole strategies on mortality among children born to mothers with HIV: A modelling study

by Shrey Mathur, Melanie Smuk, Ceri Evans, Catherine J. Wedderburn, Diana M. Gibb, Martina Penazzato, Andrew J. Prendergast Background World Health Organization (WHO) guidelines recommend cotrimoxazole prophylaxis for children who are HIV-exposed until infection is excluded and vertical transmission risk … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , | Comments Off on Estimating the impact of alternative programmatic cotrimoxazole strategies on mortality among children born to mothers with HIV: A modelling study

The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study

by Keri N. Althoff, Cameron Stewart, Elizabeth Humes, Lucas Gerace, Cynthia Boyd, Kelly Gebo, Amy C. Justice, Emily P. Hyle, Sally B. Coburn, Raynell Lang, Michael J. Silverberg, Michael A. Horberg, Viviane D. Lima, M. John Gill, Maile Karris, Peter … Continue reading

Posted in Uncategorized | Tagged , , , , , , , , , , , , , , , , | Comments Off on The forecasted prevalence of comorbidities and multimorbidity in people with HIV in the United States through the year 2030: A modeling study